Cook Richard J, Coleman Robert, Brown Janet, Lipton Allan, Major Pierre, Hei Yong Jiang, Saad Fred, Smith Matthew R
Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269.
To evaluate the relative prognostic value for specific markers of osteoblast and osteoclast activity while controlling for previously reported prognostic variables among men with hormone-refractory metastatic prostate cancer.
The 643 subjects in this report were participants in multicenter randomized controlled trial of zoledronic acid in men with metastatic prostate cancer. All subjects had bone metastases and disease progression despite medical or surgical castration. Relationships between baseline covariates and overall survival were examined by Cox proportional hazard model. Serum bone-specific alkaline phosphatase (BAP) and urinary N-telopeptide were assessed as representative specific markers of osteoblast and osteoclast activity, respectively. Other covariates in the model were age, log prostate-specific antigen, hemoglobin, lactate dehydrogenase, albumin, analgesic use, and Eastern Cooperative Oncology Group performance status.
Serum BAP was significantly correlated with urinary N-telopeptide (correlation coefficient = 0.674; 95% confidence interval, 0.628-0.715; P < 0.0001). In univariate analyses, higher levels of serum BAP and urinary N-telopeptide levels were significantly associated with shorter overall survival. After controlling for the other variables, including N-telopeptide, in multivariate models, higher serum BAP levels were consistently associated with shorter survival. In contrast, urinary N-telopeptide levels were not significantly associated with survival in multivariate analyses. Variables retained in the reduced multivariate model were age, log prostate-specific antigen, hemoglobin, lactate dehydrogenase, analgesic use, and BAP.
Serum BAP significantly correlates with urinary N-telopeptide in men with androgen-independent prostate cancer and bone metastases. In multivariate models, higher levels of serum BAP but not urinary N-telopeptide are associated with shorter overall survival.
在控制先前报道的激素难治性转移性前列腺癌男性患者预后变量的同时,评估成骨细胞和破骨细胞活性特定标志物的相对预后价值。
本报告中的643名受试者参与了一项多中心随机对照试验,该试验针对转移性前列腺癌男性患者使用唑来膦酸。所有受试者均有骨转移且尽管接受了药物或手术去势治疗仍有疾病进展。通过Cox比例风险模型检查基线协变量与总生存期之间的关系。血清骨特异性碱性磷酸酶(BAP)和尿N-端肽分别作为成骨细胞和破骨细胞活性的代表性特定标志物进行评估。模型中的其他协变量包括年龄、前列腺特异性抗原对数、血红蛋白、乳酸脱氢酶、白蛋白、镇痛药物使用情况以及东部肿瘤协作组体能状态。
血清BAP与尿N-端肽显著相关(相关系数 = 0.674;95%置信区间,0.628 - 0.715;P < 0.0001)。在单变量分析中,血清BAP和尿N-端肽水平较高与较短的总生存期显著相关。在多变量模型中控制了包括N-端肽在内的其他变量后,较高的血清BAP水平始终与较短的生存期相关。相比之下,在多变量分析中尿N-端肽水平与生存期无显著关联。简化多变量模型中保留的变量有年龄、前列腺特异性抗原对数、血红蛋白、乳酸脱氢酶、镇痛药物使用情况和BAP。
在雄激素非依赖性前列腺癌伴骨转移的男性患者中,血清BAP与尿N-端肽显著相关。在多变量模型中,较高的血清BAP水平而非尿N-端肽水平与较短的总生存期相关。